Eli Lilly experienced a significant stock increase after revealing that its new pill performed as effectively as Ozempic, a leading drug in the market. This development highlights the potential competition Lilly could pose in the pharmaceutical sector. The results have been well-received by investors, driving up the company’s valuation.
— new from Bloomberg.com
